Chimeric Competitors

Pink Sheets . USA . 
Stock . Chimeric Therapeutics Limited
CHMMF Stock   0  0.00  0.00%   
Chimeric Therapeutics competes with XOMA Corp, XOMA, Imugene, Fortress Biotech, and RemeGen; as well as few others. Analyzing Chimeric Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Chimeric Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Chimeric Therapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Chimeric Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.0000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.00080.00
Details
Naive
Forecast
LowNextHigh
000
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
000
Details

Chimeric Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Chimeric Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Chimeric and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Chimeric Therapeutics does not affect the price movement of the other competitor.

High positive correlations

XOMAO
+ 0.9
XOMAP
DWAY
+ 0.66
IUGNF
FMZNF
+ 0.5
XOMAO
FMZNF
+ 0.48
XOMAP
CEIEF
+ 0.43
FBIOP
CEIEF
+ 0.3
IUGNF
  

High negative correlations

IUGNF
- 0.79
XOMAP
IUGNF
- 0.77
XOMAO
DWAY
- 0.62
FMZNF
DWAY
- 0.6
XOMAO
CEIEF
- 0.58
XOMAO
FMZNF
- 0.55
IUGNF

Risk-Adjusted Indicators

There is a big difference between Chimeric Pink Sheet performing well and Chimeric Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Chimeric Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
XOMAP  0.45  0.04 (0.08) 4.20  0.47 
(0.65)
 1.15 
(1.06)
 3.14 
XOMAO  0.31  0.03 (0.09) 0.31  0.30 
(0.37)
 0.72 
(0.55)
 2.74 
IUGNF  11.68  0.03  0.00  0.06  0.00 
 0.00 
 26.09 
(25.93)
 130.33 
FBIOP  2.76  0.38  0.10  0.77  2.88 
(3.17)
 8.23 
(5.60)
 21.33 
REGMF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
FMZNF  8.58  3.24  0.00 (1.27) 0.00 
 0.00 
 10.81 
(2.63)
 191.73 
LEKOF  1.21  0.24  0.00 (0.19) 0.00 
 0.00 
 0.00 
 0.00 
 68.57 
DWAY  7.41  2.46  0.06 (0.20) 9.52 
(62.85)
 11.28 
(12.50)
 229.99 
CEIEF  0.96 (0.04) 0.00 (0.85) 0.00 
 0.00 
 3.33 
(4.76)
 11.62 
All Fundamental Data

Chimeric Therapeutics Competitive Analysis

The better you understand Chimeric Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Chimeric Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Chimeric Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CHMMF XOMAP XOMAO IUGNF FBIOP REGMF FMZNF LEKOF DWAY CEIEF
 0.00 
 0 
Chimeric
 0.47 
 25.65 
XOMA
 0.32 
 25.45 
XOMA
 16.67 
 0.21 
Imugene
 10.21 
 7.88 
Fortress
 0.00 
 5.06 
RemeGen
 46.67 
 0.44 
Family
 0.00 
 0.01 
Lekoil
 3.33 
 0.06 
DriveItAway
 4.84 
 0.59 
Coelacanth
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Out of control
Slightly risky
Very steady
Out of control
Out of control
Out of control
Extremely Dangerous
Market Performance
(90 Days Performance)
Weakest
Mild
Fair
Weakest
Mild
Weakest
Fair
Weak
Soft
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Low
High
Average
Low
Average
Strong
Strong
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Fairly Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Buy
Cautious Hold
Strong Sell
Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
10.36
10.36
15.32
2.85
7.48
1.09
0.32
0.53
N/A
Net Asset
34.88 M
166.56 M
166.56 M
147.61 M
396.5 M
4.16 B
240.69 M
135.22 M
293.12 K
N/A
Profit Margin
N/A
0.46
0.46
-2.92
-1.17
0.15
-1.42
-2.25
N/A
N/A
EBITDA
(14.14 M)
16.36 M
16.36 M
(37.56 M)
(46.05 M)
281.58 M
(52.8 M)
(237.16 M)
(716.73 K)
N/A
Operating Margin
-5.57
0.47
0.47
-2.91
-2.63
0.0244
-1.33
-2.52
-21.35
N/A
Current Valuation
56.81 K
215.07 M
213.66 M
737.79 M
2.58 B
5.29 B
155.08 M
12.95 M
4.94 M
211.37 M
Price To Book
1.49
N/A
N/A
8.51
N/A
14.84
1.73
0.0201
4.02
N/A
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(35 M)
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
11 M
N/A
N/A
Beta
N/A
0.94
0.94
2.06
1.9
0.34
1.47
0.64
N/A
N/A
Number Of Employees
7
12
12
17
173
2.12 K
420
27
N/A
7
Shares Outstanding
437.09 M
N/A
N/A
6.42 B
56.68 M
189.58 M
902.21 M
758.78 M
106.55 M
425.11 M
Cash Flow From Operations
(13.15 M)
22.68 M
22.68 M
(30.85 M)
(116.54 M)
263.63 M
(37.27 M)
(187 K)
(827.61 K)
N/A
Annual Yield
N/A
0.0861
0.0838
N/A
0.12
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
133 K
133 K
673.43 K
46.56 M
46.52 M
203.34 K
13.41 M
292.2 K
535 K
Return On Equity
-0.63
0.15
0.15
-0.37
-1.43
0.0634
-0.64
-1.0
N/A
N/A
Z Score
N/A
N/A
N/A
N/A
1.2
18.0
N/A
-3.3
-0.6
N/A
Return On Asset
-0.26
0.0866
0.0866
-0.21
-0.35
0.01
-0.25
-0.41
-4.57
N/A
Book Value Per Share
0.06
11.38
11.38
0.024
0.57
9.73
0.2
0.13
-0.01
0.23
Number Of Shares Shorted
N/A
2.82 K
3.41 K
N/A
245
N/A
N/A
N/A
N/A
N/A
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
19 M
N/A
N/A
Total Asset
34.88 M
166.56 M
166.56 M
147.61 M
396.5 M
4.16 B
240.69 M
135.22 M
293.12 K
N/A
Debt To Equity
N/A
0.001
0.001
0.004
0.81
0.008
0.027
0.24
1.87
0.005
Short Ratio
N/A
1.45
0.46
N/A
0.02
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
3.79
N/A
8.67
1.8
29.23
25.23
16.13
N/A
16.6
Market Capitalization
26.23 M
N/A
N/A
642.17 M
107.79 M
1.42 B
193.43 M
9.62 M
3.13 M
243.37 M
Price To Earning
N/A
292.32
288.41
N/A
N/A
264.15
N/A
2.12
N/A
N/A
Price To Sales
10.02
N/A
N/A
61.84
1.36
3.65
4.28
0.2
145.91
N/A
Net Income
(15.9 M)
15.8 M
15.8 M
(37.87 M)
(164.83 M)
276.26 M
(64.02 M)
(237.16 M)
(1.48 M)
N/A
Earnings Per Share
N/A
1.0
1.0
-0.004
-0.86
0.08
-0.054
-0.19
N/A
N/A
Shares Owned By Insiders
47.75
N/A
N/A
15.4
N/A
33.99
30.42
N/A
78.9
30.47
Revenue
2.62 M
38.16 M
38.16 M
12.97 M
68.79 M
1.42 B
44.73 M
N/A
55.51 K
N/A
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(8 M)
N/A
N/A
Cash And Equivalents
N/A
83.7 M
83.7 M
99.89 M
248.77 M
3.82 B
32.75 M
3.2 M
389.66 K
72.75 M
Cash Per Share
N/A
7.31
7.31
0.02
2.31
7.08
0.04
0.01
N/A
0.17
Gross Profit
2.62 M
37.99 M
37.99 M
12.97 M
(85.66 M)
1.36 B
30.58 M
13.28 M
16.61 K
N/A
Day Typical Price
0.001
25.65
25.43
0.19
7.75
5.06
0.44
0.01
0.058
0.59
Accumulation Distribution
N/A
N/A
0.0024
0.29
0.0727
N/A
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
N/A
0.06
0.06
0.58
N/A
N/A
N/A
N/A
N/A
Daily Balance Of Power
0.0
(9,223,372,036,855)
1.333333
0.5
1.258621
0.0
9.2 T
0.0
(9,223,372,036,855)
(9,223,372,036,855)
Period Momentum Indicator
N/A
(0.12)
0.08
0.03
0.73
N/A
0.14
N/A
(0)
(0.03)
Rate Of Daily Change
1.0
1.0
1.0
1.17
1.1
1.0
1.47
1.0
0.97
0.95
Day Median Price
0.001
25.65
25.42
0.18
7.69
5.06
0.44
0.01
0.058
0.59
Price Action Indicator
N/A
(0.06)
0.07
0.045
0.55
N/A
0.07
N/A
(0)
(0.01)
Relative Strength Index
N/A
34.87
95.78
84.46
24.45
N/A
33.33
33.33
62.24
4.0
Coefficient Of Variation
N/A
1354.37
758.46
(32,245)
883.55
N/A
787.65
3519.62
1673.86
(6,629)
Mean Deviation
N/A
0.4536
0.3061
11.68
2.76
N/A
8.58
1.21
7.41
0.9582
Jensen Alpha
N/A
0.0362
0.033
0.0282
0.3817
N/A
3.24
0.2401
2.46
(0.04)
Total Risk Alpha
N/A
(0.04)
(0.01)
(2.47)
(0.06)
N/A
(0.0004)
(0.61)
(1.91)
(0.30)
Sortino Ratio
N/A
(0.08)
(0.09)
N/A
0.1026
N/A
N/A
N/A
0.0638
N/A
Downside Variance
N/A
0.4879
0.2505
N/A
11.12
N/A
N/A
N/A
625.56
N/A
Standard Deviation
N/A
0.6361
0.4302
18.94
3.91
N/A
23.89
6.09
28.4
2.02
Kurtosis
N/A
0.3314
3.36
6.32
1.89
N/A
32.68
35.97
51.98
3.4
Potential Upside
N/A
1.15
0.7151
26.09
8.23
N/A
10.81
N/A
11.28
3.33
Treynor Ratio
N/A
4.2
0.3065
0.0639
0.7688
N/A
(1.27)
(0.19)
(0.20)
(0.85)
Maximum Drawdown
N/A
3.14
2.74
130.33
21.33
N/A
191.73
68.57
229.99
11.62
Variance
N/A
0.4046
0.185
358.71
15.28
N/A
570.88
37.14
806.82
4.08
Market Risk Adjusted Performance
N/A
4.21
0.3165
0.0739
0.7788
N/A
(1.26)
(0.18)
(0.19)
(0.84)
Risk Adjusted Performance
N/A
0.0514
0.0874
0.0074
0.0889
N/A
0.1002
0.0291
0.0523
(0)
Skewness
N/A
0.0736
(0.64)
1.45
0.8326
N/A
5.1
2.76
6.55
0.228
Semi Deviation
N/A
0.475
0.3015
N/A
2.88
N/A
N/A
N/A
9.52
N/A
Information Ratio
N/A
(0.08)
(0.10)
(0.01)
0.0875
N/A
0.1228
0.012
0.0562
(0.06)
Value At Risk
N/A
(1.06)
(0.55)
(25.93)
(5.60)
N/A
(2.63)
N/A
(12.50)
(4.76)
Expected Short fall
N/A
(0.65)
(0.37)
N/A
(3.17)
N/A
N/A
N/A
(62.85)
N/A
Downside Deviation
N/A
0.6985
0.5005
N/A
3.33
N/A
N/A
N/A
25.01
N/A
Semi Variance
N/A
0.2256
0.0909
N/A
8.27
N/A
N/A
N/A
90.57
N/A

Chimeric Therapeutics Competition Performance Charts

Five steps to successful analysis of Chimeric Therapeutics Competition

Chimeric Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Chimeric Therapeutics in relation to its competition. Chimeric Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Chimeric Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Chimeric Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Chimeric Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Chimeric Therapeutics position

In addition to having Chimeric Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Stores Thematic Idea Now

Stores
Stores Theme
Companies providing different types of retail and wholesale services. The Stores theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Stores Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Chimeric Pink Sheet

Chimeric Therapeutics financial ratios help investors to determine whether Chimeric Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chimeric with respect to the benefits of owning Chimeric Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY